Feb. 25 at 9:15 PM
$MRVI Q4 '25 Earnings Results & Recap
• Reported GAAP EPS of -
$0.24 down -33.33% YoY
• Reported revenue of
$49.87M down -11.83% YoY
• Maravai LifeSciences introduced full year 2026 revenue guidance ranging from
$200M to
$210M and full year 2026 Adjusted EBITDA guidance ranging from
$18M to
$20M.
